查詢結果分析
來源資料
頁籤選單縮合
題名 | Immunoglobulin M Antibody Response to Hepatitis C Virus Core Protein in Patients with Chronic Hepatitis C=慢性C型肝炎患者之IgM核心抗體反應及對治療反應之預測價值 |
---|---|
作者 | 高嘉宏; 賴明陽; 陳培哲; 陳定信; | 書刊名 | 臺灣醫學會雜誌 |
卷期 | 96:10 1997.10[民86.10] |
頁次 | 頁825-828 |
分類號 | 415.5332 |
關鍵詞 | 慢性C型肝炎患者; IgM核心抗體反應; Chronic hepatitis C; IgM anti-HCVcore; Combination therapy; HCV genotype; HCV RNA; |
語文 | 英文(English) |
英文摘要 | We retrospectively assessed the frequency and clinicopathologic and virolgic significance of production of immunoglobulin M (IgM) antibody to hepatitis C virus (HCV) core protein in patients with chronic hepatitis C. Sera from 60 patients with chronic hepatitis C were tested for IgM anti-HCV core (anti-HCc). Twenty of these patients received ribavirin plus interferon- α for 24 weeks, and were classified as sustained, transient, or nonresponders on the basis of alanine aminotransferase levels and the presence of HCV RNA at the end of treatment and 24 weeks later. IgM anti- HCc was detected in 21 patients. There was no correlation between the presence of IgM anti-HCc and clinical features such as sex, age, mode of transmission, serum levels of alanine aminotransferase, HCV genotype, serum HCV titer, or histologic findings. Among the patients who received ribavirin plus interferon- α, the mean IgM anti-HCc level before therapy was comparable between sustained (n=10), transient (n=8), and nonresponders (n=2). A statistically significant decrease in IgM anti-HCc response during antiviral therapy was observed in the 18 responders who became negative for serum HCV RNA at the end of therapy. These data suggest that IgM anti-HCc is of limited clinical usefulness as a marker of chronic HCV infection. Serial testing for IgM anti-HCc may provide a marker of antiviral response. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。